US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Onestream Inc

21.05

-0.0500-0.24%

Volume:178.27K

Turnover:3.76M

Market Cap:3.71B

PE:-16.87

High:21.36

Open:21.12

Low:20.94

Close:21.10

Loading ...

Overview Company News Filings

GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting

Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development

Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST

KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer

Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

AbbVie Reports First-Quarter 2025 Financial Results

OneStream Is Maintained at Sector Outperform by Scotiabank

Bristol Myers Squibb Reports First Quarter Financial Results for 2025

Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma

Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More

BNP Paribas Exane Initiates Coverage on Onestream With Outperform Rating, $30 Price Target

MT Newswires Live

OS Therapies FDA Meeting Request Granted

Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer

Health Canada Approves KEYTRUDA® Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)

Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/OS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","market":"US","secType":"STK","nameCN":"Onestream Inc","latestPrice":21.05,"timestamp":1745946480916,"preClose":21.1,"halted":0,"volume":178271,"delay":0,"floatShares":70199725,"shares":176023203,"eps":-1.247698,"marketStatus":"Trading","change":-0.05,"latestTime":"04-29 13:08:02 EDT","open":21.12,"high":21.36,"low":20.94,"amount":3759576.7288100002,"amplitude":0.019905,"askPrice":21.08,"askSize":1,"bidPrice":21.05,"bidSize":196,"shortable":3,"etf":0,"ttmEps":-1.247698,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745956800000},"marketStatusCode":2,"adr":0,"listingDate":1721793600000,"exchange":"NASDAQ","adjPreClose":21.1,"preHourTrading":{"tag":"盘前","latestPrice":21.01,"preClose":21.1,"latestTime":"04:37 EDT","volume":7,"amount":148.56999499999998,"timestamp":1745915844247},"postHourTrading":{"tag":"盘后","latestPrice":21.1,"preClose":21.1,"latestTime":"19:21 EDT","volume":16320,"amount":344351.84,"timestamp":1745882517004},"volumeRatio":0.408143,"impliedVol":0.8896,"impliedVolPercentile":0.9574},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","floatShares":70199725,"roa":"-33.71%","roe":"-102.65%","lyrEps":-1.232998,"volumeRatio":0.408143,"shares":176023203,"dividePrice":0,"high":21.36,"amplitude":0.019905,"preClose":21.1,"low":20.94,"week52Low":16.6942,"pbRate":"9.59","psRate":"7.57","week52High":35.39,"institutionHeld":0,"latestPrice":21.05,"committee":0.989848,"eps":-1.247698,"divideRate":0,"volume":178271,"delay":0,"ttmEps":-1.247698,"open":21.12,"prevYearClose":28.52,"prevWeekClose":21.29,"prevMonthClose":21.34,"prevQuarterClose":21.34,"fiveDayClose":19.79,"twentyDayClose":21.34,"sixtyDayClose":29.78,"earningDate":1746633600000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531765670","title":"GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2531765670","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531765670?lang=en_us&edition=fundamental","pubTime":"2025-04-30 00:00","pubTimestamp":1745942400,"startTime":"0","endTime":"0","summary":"Advancing Gene-Directed Prodrug Therapy: Data Presented at AACR Supports Gedeptin's Potential in Solid Tumors. ATLANTA, GA - April 29, 2025  - GeoVax Labs, Inc. , a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of new clinical data on its gene-directed enzyme prodrug therapy, Gedeptin, at the American Association for Cancer Research  Annual Meeting 2025, being held April 2530 in Chicago, IL.The presentation, titled \"Viral-Vectored, Gene-Directed Prodrug Therapy  in Needle-Accessible Solid Tumors,\" was delivered by J. Marc Pipas, M.D., Executive Medical Director, Oncology at GeoVax, during the Phase II Clinical Trials 1 Poster Session on April 29, 2025. The session drew significant interest from researchers and clinicians, underscoring the growing recognition of Gedeptin's therapeutic potential. The corresponding abstract was published in the AACR journal Cancer Research.\"These clini","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-presents-gedeptin-r-clinical-160000847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4211","SD","GOVX","BK4117","LU1814569148.SGD","LU2362541273.HKD","LU2517655028.SGD","LU2517655374.HKD","AFG","BK4022","BK4588","BK4097","IT","PFS","R","OS","LU2517655291.USD","LU2362540622.SGD","LU0154245673.USD","LU0154245756.USD","LU2362541513.USD","BK4213","LU0107464264.USD","BK4139","BK4107","BK4232","BK4134","BK4195","BK4583","BK4585"],"gpt_icon":0},{"id":"2531759499","title":"Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2531759499","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531759499?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:00","pubTimestamp":1745935200,"startTime":"0","endTime":"0","summary":"An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer  who received AFM24 at 480 mg weekly demonstrates that higher drug exposure  leads to improved objective response rate  and longer progression free survival   without a negative impact on safety. These findings will be incorporated in future AFM24 trials to further improve efficacy outcomes of patients treated with AFM24. MANNHEIM, Germany, April 29, 2025  -- Affimed N.V. , a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented findings on an exposure-outcome analysis of its innate cell engager  AFM24, in patients with advanced or metastatic non-small cell lung cancer  in a poster session at the 2025 Annual Meeting of the American Association for Cancer Research .The analysis is based on post-hoc exposure-response data from 72 NSCLC patients treated with 480 mg of AFM24 monotherapy or a combination of AFM24 with atezolizumab. F","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/affimed-shows-higher-exposure-afm24-140000007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ORR","PFS","BK4181","BK4195","BK4139","BK4218","PK","BK4211","AFMD","OS","BK4097"],"gpt_icon":0},{"id":"2531816437","title":"Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2531816437","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531816437?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:45","pubTimestamp":1745923500,"startTime":"0","endTime":"0","summary":"Delivers Robust Earnings Performance, Successfully Navigating a Dynamic Environment. NEW YORK, April 29, 2025----Pfizer Inc.  reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance.\"Our overall solid first-quarter performance demonstrates our continued focus on commercial execution amid U.S. Medicare Part D headwinds. Our focus on operational efficiency and financial discipline is driving strong results to our bottom line. We are currently trending towards the upper end of our 2025 Adjusted diluted EPS guidance range.\". First-Quarter 2025 Revenues of $13.7 Billion, Reported Diluted EPS of $0.52, and Adjusted Diluted EPS of $0.92. On Track to Deliver Operating Margin Expansion from Ongoing Cost Realignment Program with Approximately $4.5 Billion of Net Cost Savings by End of 2025, and Announces Additional Productivity Gains Expected Through 2027 Leveraging Digital Enablement and Process Simplification. First Phase of Manufacturing Optimizatio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-reports-solid-first-quarter-104500122.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SGXZ57979304.SGD","LU0289739699.SGD","IE00B19Z3581.USD","BK4533","BK4599","LU0868494617.USD","LU1066051498.USD","PFS","LU1894683264.USD","LU0321505868.SGD","LU1894683348.USD","CDC","LU0225284248.USD","BK4213","SG9999002232.USD","BK4550","BNTX","IE0002270589.USD","ITT","LU0058720904.USD","BK4535","PFE","LU1057294990.SGD","LU0122379950.USD","BK4585","BK4568","EC","IE000M9KFDE8.USD","BK4230","OS","LU0053671581.USD","BCG","BK4135","IE00BLSP4452.SGD","LU0054578231.USD","SG9999002224.SGD","BK4548","SG9999013999.USD","LU1066053197.SGD","LU0321505439.SGD","LU0234572021.USD","BK4195","BK4022","BK4581","LU0225771236.USD","BK4534","LU0170899867.USD","SOC","CAR"],"gpt_icon":1},{"id":"2530147098","title":"BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2530147098","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530147098?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:30","pubTimestamp":1745839800,"startTime":"0","endTime":"0","summary":"Overall survival and clinical benefit in Phase 2 continue to outperform historical benchmarks, including very heavily pretreated patients. Clinical benefit observed in 83% of evaluable patient sub-group treated with the phase 3 formulation. Improved new Bria-OTS+ platform provides powerful innate and adaptive immune system activation. Title:Survival outcomes in a randomized phase 2 ofBria-IMT: An allogeneic whole cell cancer vaccineSession Title:Phase II and Phase III Clinical TrialsSession Start:4/28/2025 2:00 PM – 5:00 PM CSTLocation:Poster Section 50Poster Board Number:18Abstract Presentation Number:CT100. “We are thrilled to share impressive survival and clinical efficacy data at AACR on the advantages of using Bria-IMT plus checkpoint inhibitor in heavily treated patients who have failed multiple prior treatments, including ADCs and CPIs,” stated lead author, Saranya Chumsri, MD, Principal Investigator and Professor of Oncology, Mayo Clinic. “Treatment options have been limited fo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-presents-benchmark-beating-survival-113000613.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BCTXZ","OS","BCTX","BK4097","BCTXW","ORR"],"gpt_icon":0},{"id":"2530040513","title":"Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST","url":"https://stock-news.laohu8.com/highlight/detail?id=2530040513","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530040513?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:30","pubTimestamp":1745839800,"startTime":"0","endTime":"0","summary":"– Phase 1 dose-escalation study to evaluate ziftomenib in combination with imatinib in patients with advanced GIST after imatinib failure –。– Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive and imatinib-resistant GIST preclinical models –。SAN DIEGO, April 28, 2025  -- Kura Oncology, Inc. , a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the first patients have been dosed in KOMET-015, a Phase 1 clinical trial of ziftomenib, the Company’s potent and selective, oral investigational menin inhibitor, in patients with advanced gastrointestinal stromal tumors  after imatinib failure.“Until now, most approaches to treating gastrointestinal stromal tumors rely on targeted KIT inhibition via tyrosine kinase inhibitors such as imatinib, however most patients eventually progress due to acquired secondary KIT mutations highlighting the need","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kura-oncology-announces-first-patients-113000397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","IE00B66KJ199.SGD","BK4139","OS","BK4505","BK4195","AEIS","LU0054578231.USD","BK4211","BK4157","BK4179","IE00B7SZL793.SGD","IE00BD6J9T35.USD","IE00B19Z4B17.USD","ORR","KURA","PFS","FTI","IE0031619046.USD","LU0053671581.USD","LU0300736062.USD","LU0300736492.USD"],"gpt_icon":0},{"id":"2530548354","title":"KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2530548354","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530548354?lang=en_us&edition=fundamental","pubTime":"2025-04-28 00:00","pubTimestamp":1745769600,"startTime":"0","endTime":"0","summary":"KEYNOTE-689 marks the first positive trial in more than two decades for patients with resected locally advanced head and neck squamous cell carcinoma . Results to be presented at American Association for Cancer Research  Annual Meeting 2025 during a Plenary Session and included in official meeting press program. \"As the first positive trial in over two decades for patients with resectable, locally advanced head and neck squamous cell carcinoma, the presentation of these landmark results marks an important moment for these patients and those who care for them,\" said Dr. Ravindra Uppaluri, the study’s co-principal investigator, director of Head and Neck Surgical Oncology, Brigham and Women’s Hospital and Dana-Farber","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/keytruda-pembrolizumab-perioperative-treatment-standard-160000135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1037948541.HKD","LU2106854487.HKD","BK4161","DM","LU2361044949.HKD","LU2023250843.SGD","BCG","LU1066051225.USD","LU1861220033.SGD","LU0265550946.USD","LU0054578231.USD","IE00BLSP4452.SGD","ITT","ALT","ON","MRK","LU0208291251.USD","LU0861579265.USD","LU0289739699.SGD","SMP","CRT","SG9999001440.SGD","IE00BLSP4239.USD","BK4135","LU0320765646.SGD","LU1162221912.USD","AEIS","SGXZ57979304.SGD","LU0320765489.SGD","IE00B7SZL793.SGD","BK4605","LU1430594728.SGD","SOC","SG9999015358.SGD","IE00BZ199S13.USD","IE0009355771.USD","BK4533","BTC","LU2361044865.SGD","RCC","OS","LU1934455194.USD","LU2298322129.HKD","HCC","CRC","LU1854103824.USD","SG9999014567.USD","CPS","HSCT","BK4097"],"gpt_icon":0},{"id":"2530175941","title":"Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2530175941","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530175941?lang=en_us&edition=fundamental","pubTime":"2025-04-27 01:50","pubTimestamp":1745689800,"startTime":"0","endTime":"0","summary":"Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response  with more than half of responders remaining cancer-free at one year after CR. Results reinforce potential of TAR-200 to transform outcomes for certain types of BCG-unresponsive, high-risk non-muscle invasive bladder cancer. As of March 2025, 82.4 percent of the 85 enrolled patients in the study achieved a complete response  , meaning their cancer was undetectable following treatment. This high response rate translated into sustained disease control, with 52.9 percent of responders maintaining complete response at one year. The median duration of response  was 25.8 months , indicating that many patients remained cancer-free for over two years without the need for reinduction therapy. At 12 months, 86.6 perc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/johnson-johnsons-tar-200-monotherapy-175000318.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/johnson-johnsons-tar-200-monotherapy-175000318.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2505996509.AUD","LU1061106388.HKD","CR","IE00BDGV0183.EUR","JNJ","LU1032955483.USD","LU0912757837.SGD","RC","LU1059921491.USD","OS","LU0234570918.USD","LU2468319806.SGD","LU2430703178.SGD","LU2592432038.USD","IE000M9KFDE8.USD","IE00BFTCPJ56.SGD","LU0795875086.SGD","LU1066051811.HKD","LU1244550494.USD","LU1929549753.HKD","IE00B19Z3B42.SGD","LU0466842654.USD","IE00BN8TJ469.HKD","LU0882574055.USD","IE00B7SZLL34.SGD","LU0114720955.EUR","LU1221951046.USD","LU1674673691.USD","BK4504","LU1244550221.USD","LU1718418525.SGD","LU1244550577.SGD","IE00BLSP4239.USD","LU1074936037.SGD","LU2347655156.SGD","SG9999002232.USD","LU0792757196.USD","LU1914381329.SGD","LU1894683264.USD","IE00B2B36J28.USD","LU0345769128.USD","BCG","LU0203347892.USD","BK4533","LU2129689431.USD","LU2089984988.USD","LU0345769631.USD","IE00B1BXHZ80.USD","LU1023059063.AUD"],"gpt_icon":0},{"id":"2530175929","title":"Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2530175929","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530175929?lang=en_us&edition=fundamental","pubTime":"2025-04-27 01:30","pubTimestamp":1745688600,"startTime":"0","endTime":"0","summary":"Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab in combination with standard of care  Bacillus Calmette-Guérin  regimen compared to SOC alone. Sasanlimab, a subcutaneously administered PD-1 inhibitor, in combination with BCG represents the first potential treatment advancement for BCG-nave, high-risk non-muscle invasive bladder cancer in more than 30 years. Results have been shared with global health authorities to support potential regulatory filings. \"New bladder cancer treatment options that help reduce rates of disease recurrence or progression are long overdue. Up to 50% of patients with high-risk non-muscle invasive bladder cancer may experience failure of BCG intravesical immunotherapy, yet it has been the standard of care after tumor resection for decades,\" said Neal Shore, M.D., FACS, Medical Director for START Carolina Research Center, and lead investigator ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-sasanlimab-combination-significantly-improves-173000786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4592","IE0002270589.USD","LU1066053197.SGD","LU0225771236.USD","LU1057294990.SGD","BK4231","BCG","BK4585","IE00BLSP4239.USD","BK4550","BK4581","LU0985481810.HKD","IE00BSNM7G36.USD","BK4203","PFE","SG9999002232.USD","ADC","BK4588","LU0289739699.SGD","LU0170899867.USD","LU1261432733.SGD","SG9999001176.USD","LU1023059063.AUD","SG9999011175.SGD","BK4533","BK4534","IE00BBT3K403.USD","LU0321505439.SGD","CI","HR","LU1059921491.USD","BK4213","LU0234572021.USD","BK4007","BK4097","SG9999003800.SGD","SG9999002224.SGD","CR","LU0306806265.USD","SG9999013999.USD","OS","LU0456855351.SGD","LU1883839398.USD","SOC","BK4135","SGXZ57979304.SGD","LU1894683348.USD","LU0122379950.USD","IE000M9KFDE8.USD"],"gpt_icon":1},{"id":"2530685901","title":"ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2530685901","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530685901?lang=en_us&edition=fundamental","pubTime":"2025-04-26 01:10","pubTimestamp":1745601000,"startTime":"0","endTime":"0","summary":"- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide  was well-tolerated and demonstrated promising anti-tumor activity. - Combination generated complete responses  in 83% of patients with indolent relapsed or refractory B-cell non-Hodgkin lymphoma  comparing favorably to 34% historical CR rate with R2 alone. - Phase 2 portion of trial in patients with previously untreated indolent NHL  is ongoing and has completed enrollment. After a median follow-up of 28 months  the two-year progression-free survival  rate was 69% and two-year overall survival  rate was 84%. Sixteen patients (80%) achieved complete responses and the best overall response rate  was 90%. As previously repo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alx-oncology-announces-encouraging-final-171000715.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4124","BK4211","BK4139","CR","ALXO","SMP","ORR","PFS","BK4231","ALX","BK4161","BK4195","OS","BK4097","BK4080"],"gpt_icon":0},{"id":"2530513653","title":"ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2530513653","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530513653?lang=en_us&edition=fundamental","pubTime":"2025-04-25 21:00","pubTimestamp":1745586000,"startTime":"0","endTime":"0","summary":"In ASPEN-03 and ASPEN-04 trials, efficacy data do not support advancing evorpacept in combination with Merck’s anti-PD-1 therapy, KEYTRUDA , into a registrational study. Company remains confident in continuing to pursue evorpacept in multiple clinical trials, based on the different mechanism of evorpacept in combination with anti-cancer antibodies, as evidenced by durable clinical response and consistent safety data in prior clinical trials. In the ASPEN-03 and ASPEN-04 clinical trials, evorpacept was combined with pembrolizumab with or without chemotherapy to investigate a second and distinct mechanism of action. This discrete approach explored the concept that evorpacept may enhance T-cell priming by activating dendritic cells and stimulating the adaptive immune system. The trial outcomes were not sufficiently supportive of advancing evorpacept in combination with pe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alx-oncology-reports-aspen-03-130000813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BFTCPJ56.SGD","BK4516","SG9999014567.USD","LU1291159041.SGD","MRK","ALXO","IE00B1BXHZ80.USD","LU1069347547.HKD","LU0203345920.USD","LU1057294990.SGD","LU1934455863.HKD","LU2461242641.AUD","IE0002141913.USD","LU1116320901.HKD","LU1983299246.USD","LU0965509283.SGD","BK4080","LU1917777945.USD","LU1934455277.USD","BK4231","LU1934455194.USD","LU2468319806.SGD","LU1037948541.HKD","LU1989772840.SGD","LU0861579265.USD","ALX","BK4550","LU0965508806.USD","LU1116320737.USD","IE00B2B36J28.USD","LU1941712264.USD","LU1066051811.HKD","LU1093756325.SGD","LU2089984988.USD","LU1974910355.USD","LU0265550946.USD","LU1035773651.USD","LU2106854487.HKD","LU0211331839.USD","PFS","ORR","SG9999001176.USD","IE00BN8TJ469.HKD","BK4097","LU1037948897.HKD","IE000M9KFDE8.USD","SG9999014542.SGD","SG9999014559.SGD","LU0234572021.USD","OS"],"gpt_icon":0},{"id":"2530184200","title":"AbbVie Reports First-Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2530184200","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530184200?lang=en_us&edition=fundamental","pubTime":"2025-04-25 19:43","pubTimestamp":1745581380,"startTime":"0","endTime":"0","summary":"Reports First-Quarter Diluted EPS of $0.72 on a GAAP Basis, a Decrease of 6.5 Percent; Adjusted Diluted EPS of $2.46, an Increase of 6.5 Percent; These Results Include an Unfavorable Impact of $0.13 Per Share Related to Acquired IPR&D and Milestones Expense. Delivers First-Quarter Net Revenues of $13.343 Billion, an Increase of 8.4 Percent on a Reported Basis or 9.8 Percent on an Operational Basis. First-Quarter Global Net Revenues from the Immunology Portfolio Were $6.264 Billion, an Increase of 16.6 Percent on a Reported Basis, or 18.1 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $3.425 Billion; Global Rinvoq Net Revenues Were $1.718 Billion; Global Humira Net Revenues Were $1.121 Billion. First-Quarter Global Net Revenues from the Oncology Portfolio Were $1.633 Billion, an Increase of 5.8 Percent on a Reported Basis, or 7.5 Percent on an Operational Basis; Global Imbruvica Net Revenues Were $738 Million; Global Venclexta Net Revenues Were $665 Million; Global El","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/abbvie-reports-first-quarter-2025-114300471.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbvie-reports-first-quarter-2025-114300471.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0882574055.USD","LU0203347892.USD","IE0002141913.USD","LU1093756168.USD","LU0114720955.EUR","BK4211","LU0965508806.USD","PFS","BK4201","ABBV","IE0004445239.USD","LU1989772840.SGD","LU0708994859.HKD","LU2237443465.HKD","IE00B19Z3581.USD","EC","IE00B19Z3B42.SGD","BK4588","LU0128525929.USD","LU2468319806.SGD","LU1244550221.USD","BK4559","IE00BJT1NW94.SGD","LU0029864427.USD","BK4581","SG9999015978.USD","BK4534","SG9999015986.USD","LU2129689514.USD","LU1496350502.SGD","IE00BDGV0183.EUR","BK4566","LU0456855351.SGD","LU1839511570.USD","LU2129689431.USD","LU1244550494.USD","LU1929549753.HKD","CEO","LU2237443549.SGD","LU0122379950.USD","LU0310799852.SGD","LU2237443895.HKD","PROC","LU2089283258.USD","LU1093756325.SGD","IE00BVYPNV92.GBP","OS","LU2237443978.SGD","LU0310800379.SGD"],"gpt_icon":0},{"id":"2529373259","title":"OneStream Is Maintained at Sector Outperform by Scotiabank","url":"https://stock-news.laohu8.com/highlight/detail?id=2529373259","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529373259?lang=en_us&edition=fundamental","pubTime":"2025-04-24 22:39","pubTimestamp":1745505540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 24, 2025 10:39 ET (14:39 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS"],"gpt_icon":0},{"id":"2529193600","title":"Bristol Myers Squibb Reports First Quarter Financial Results for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529193600","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529193600?lang=en_us&edition=fundamental","pubTime":"2025-04-24 18:59","pubTimestamp":1745492340,"startTime":"0","endTime":"0","summary":"Results Reflect Continued Growth Portfolio Momentum and Disciplined Execution. Raising 2025 revenue guidance to a range of ~$45.8 billion to $46.8 billion; Increasing non-GAAP EPS range to $6.70 to $7.00. PRINCETON, N.J., April 24, 2025----Bristol Myers Squibb  today reports results for the first quarter of 2025.\"Our strong execution in the first quarter drove continued momentum across our Growth Portfolio and meaningful progress in the pipeline,\" said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. \"We are advancing our multi-year plan to become a more agile and efficient company, while strengthening the foundation for top-tier, long-term growth. Our strategy is clear, and our actions are accelerating the delivery of transformational medicines to patients.\". International revenues of $3.3 billion decreased 2%, or increased 2% Ex-FX.Growth Portfolio revenues of $5.6 billion increased 16% on a reported basis, or 18% Ex-FX. Revenue growth was pr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bristol-myers-squibb-reports-first-105900905.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2242652126.USD","LU0114720955.EUR","BK4007","IE00BSNM7G36.USD","LU2133065610.SGD","LU0306806265.USD","LU1989771016.USD","LU2242646821.SGD","BK4126","LU0237698245.USD","LU1585245621.USD","IE00BFTCPJ56.SGD","LU0225284248.USD","OS","LU0868494617.USD","BK4087","LU1670710588.SGD","MYE","LU1670710661.SGD","LU1291159041.SGD","LU1868836591.USD","BK4201","LU1074936037.SGD","LU2360032135.SGD","BK4097","LU1868837136.USD","LU1868836914.USD","IE0009355771.USD","LU0985481810.HKD","HCC","BK4006","LU0882574055.USD","LU0456855351.SGD","LU1323610961.USD","LU1868836757.USD","BMY","EC","LU2125154778.USD","CHMP","IE0002141913.USD","LU1261432733.SGD","IE00B2B36J28.USD","LU0321505868.SGD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU1868837300.USD","LU1670711123.USD","LU0321505439.SGD","LU1093756325.SGD","WW"],"gpt_icon":0},{"id":"2529668143","title":"Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma","url":"https://stock-news.laohu8.com/highlight/detail?id=2529668143","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529668143?lang=en_us&edition=fundamental","pubTime":"2025-04-24 04:15","pubTimestamp":1745439300,"startTime":"0","endTime":"0","summary":"Statistically significant and clinically meaningful progression-free survival  and overall survival  data for Zepzelca  and atezolizumab  combination underscore potential of first-line maintenance therapy for extensive-stage small cell lung cancer, a much-needed advancement for patients. Long-term outcomes and survival data for Ziiherahighlight its potential to reshape the treatment paradigm for newly diagnosed HER2+ gastroesophageal cancer patients. Efficacy and safety of dordaviprone  in prospective clinical trials of adult and pediatric recurrent H3 K27M-mutant diffuse glioma patients. Jazz to host investor webcast on Tuesday, June 10 to review Zepzelca data. An oral abstract of the Phase 3 IMforte trial, which showed statistically significant and clinically meaningful survival benefit (progression-free survival (PFS) and overall survival (OS) for the combination of Zepzelca and atezolizumab (Tecentriq) for extensive-stage small cell lung cancer (ES-SCLC) patients receiving treatmen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/jazz-pharmaceuticals-showcases-transformative-data-201500637.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jazz-pharmaceuticals-showcases-transformative-data-201500637.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4197","BTC","JAZZ","BK4097","BK4162","PFS","LU0109394709.USD","LU0320765992.SGD","IE00BN0W2V16.EUR","CDC","IHC","OS","IE00BN0W2T93.GBP","ORR","BK4211","CPK","BK4533","IE00BN0W2W23.USD","LU0823416689.USD","BK4007","LU0889565916.HKD","BK4195","BK4532"],"gpt_icon":0},{"id":"2529617659","title":"Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More","url":"https://stock-news.laohu8.com/highlight/detail?id=2529617659","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529617659?lang=en_us&edition=fundamental","pubTime":"2025-04-24 00:37","pubTimestamp":1745426220,"startTime":"0","endTime":"0","summary":"This was a low-key week for the biotech sector before the onset of the first-quarter earnings season. Biotech giant Bristol Myers Squibb BMY was down on data from the schizophrenia study while Regeneron REGN was in the spotlight on updates on key drugs.Bristol Myers announced disappointing top-line results from the phase III ARISE study on schizophrenia drug Cobenfy . The study is evaluating the efficacy and safety of Cobenfy as an adjunctive treatment to atypical antipsychotics in adults with inadequately controlled symptoms of schizophrenia.Treatment with Cobenfy as an adjunctive demonstrated a 2.0-point reduction in the Positive and Negative Syndrome Scale total score compared to placebo with an atypical antipsychotic at week six. However, this data did not reach the threshold for statistical significance for the primary endpoint. Shares of BMY were down following the data announcement.Preliminary analyses suggest that Cobenfy as an adjunctive treatment to an atypical antipsychotic ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-stock-roundup-bmy-down-163700964.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1989771016.USD","LU2089984988.USD","LU0225284248.USD","LU1670711123.USD","IE00B19Z3B42.SGD","BK4532","LU1670710588.SGD","REGN","IE00B7SZLL34.SGD","BK4583","LU1839511570.USD","IE00B3T34201.USD","GILD","LU0058720904.USD","OS","LU1093756168.USD","BK4007","LU0225771236.USD","LU2133065610.SGD","CRL","BK4559","LU2023250504.SGD","SNY","LU1868837300.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","IE0002141913.USD","LU0234570918.USD","BMY","LU0306807586.USD","LU0868494617.USD","LU2362541273.HKD","IE00BKVL7J92.USD","PFS","BK4585","LU2362541513.USD","LU0306806265.USD","LU0889565916.HKD","LU2237438978.USD","LU1291159041.SGD","LU1670711040.USD","LU0053666078.USD","LU0289739699.SGD","IE0002270589.USD","LU1430594728.SGD","LU1868836914.USD","BK4097","LU1670710661.SGD","LU1093756325.SGD","BK4578"],"gpt_icon":0},{"id":"2529630300","title":"BNP Paribas Exane Initiates Coverage on Onestream With Outperform Rating, $30 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2529630300","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529630300?lang=en_us&edition=fundamental","pubTime":"2025-04-22 20:02","pubTimestamp":1745323369,"startTime":"0","endTime":"0","summary":"Onestream (OS) has an average rating of Buy and mean price target of $31.16, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OS"],"gpt_icon":0},{"id":"2529370021","title":"OS Therapies FDA Meeting Request Granted","url":"https://stock-news.laohu8.com/highlight/detail?id=2529370021","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529370021?lang=en_us&edition=fundamental","pubTime":"2025-04-22 19:40","pubTimestamp":1745322000,"startTime":"0","endTime":"0","summary":"Written response-only meeting to align analysis plan of surrogate endpoint to support Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma. NEW YORK, April 22, 2025----OS Therapies  , a clinical-stage immunotherapy and Antibody Drug Conjugate  biopharmaceutical company, today announced that the US Food & Drug Administration  granted the Company’s meeting request to gain alignment on the surrogate endpoint to support Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma. FDA granted a written response-only meeting and confirmed that its response would be received by mid-June 2025, in time for the Company to present the statistical analysis as part of the keynote presentation closing out major osteosarcoma conference MIB Factor on June 28, 2025 at 3:30pm MDT.OST-HER2, an immunotherapy for osteosarcoma ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/os-therapies-fda-meeting-request-114000147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4017","OSTX","BK4139","BK4080","ADC","BK4231","BK4097","OS","DC"],"gpt_icon":0},{"id":"2529537782","title":"Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2529537782","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529537782?lang=en_us&edition=fundamental","pubTime":"2025-04-22 19:09","pubTimestamp":1745320140,"startTime":"0","endTime":"0","summary":"Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen. CE Mark approval is supported by the Phase 3 LUNAR trial, which demonstrated the first substantial improvement in median overall survival in more than 8 years for this patient population. Optune Lua is a wearable medical device that delivers Tumor Treating Fields , a first-of-its-kind therapy for metastatic NSCLC that uses electric fields to kill cancer cells. Optune Lua is a portable device that produces alternating electric fields known as Tumor Treating Fields , which are delivered through non-invasive, wearable arrays. TTFields exert physical forces on the electrically charged components of dividing cancer cells, resulting in cell death.The CE Mark approval was supported by data from the Phase 3 LUNAR trial that compared the safety and efficacy of treatment with Optune Lua concurrent with imm","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novocure-optune-lua-receives-ce-110900612.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4534","BK4109","CE","BK4548","OS","NVCR","BK4097","BK4585","BK4082","BK4588"],"gpt_icon":0},{"id":"2529372711","title":"Health Canada Approves KEYTRUDA® Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2529372711","media":"CNW Group","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529372711?lang=en_us&edition=fundamental","pubTime":"2025-04-22 19:00","pubTimestamp":1745319600,"startTime":"0","endTime":"0","summary":"Approval is based on the results from the Phase 3 CCTG IND.227/KEYNOTE-483 trial. \"This approval marks the first combination treatment of KEYTRUDA and chemotherapy in Canada for patients with malignant pleural mesothelioma,\" says Dr. Quincy Chu, Medical Oncologist at the Cross Cancer Institute and Associate Professor at the University of Alberta. \"This combination provides a new therapeutic option for this patient group, which has limited options available and may help improve health outcomes.\". The Phase 3 component of the trial enrolled 440 patients, regardless of tumour PD-L1 expression. Patients with autoimmune disease that required systemic therapy within three years of treatment or a medical condition that required immunosuppression were ineligible. Patients were randomized (1:1) to one of the following treatment arms; all study medications were administered via intravenous infusion:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/health-canada-approves-keytruda-plus-110000111.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4516","IE00B1BXHZ80.USD","LU1430594728.SGD","BK4588","HR","LU1066051811.HKD","SG9999002224.SGD","SG9999013999.USD","IE0009355771.USD","PFS","IE00BBT3K403.USD","BK4148","LU1037948541.HKD","LU1066053197.SGD","LU1934455277.USD","LU0965509283.SGD","SG9999001176.SGD","IE00BJT1NW94.SGD","LU0203347892.USD","LU1093756325.SGD","LU1037948897.HKD","LU2089984988.USD","LU0234572021.USD","LU1571399168.USD","MRK","LU1585245621.USD","BK4211","LU0965508806.USD","IE00BSNM7G36.USD","LU0006306889.USD","CCTG","IE00B19Z4B17.USD","LU0965509101.SGD","LU0106261372.USD","LU0208291251.USD","OS","LU0265550946.USD","LU1057294990.SGD","BK4559","AEIS","IE000M9KFDE8.USD","BK4550","BK4157","LU2461242641.AUD","BK4203","ORR","LU0203345920.USD","LU1989772840.SGD","LU0266013472.USD","SGXZ57979304.SGD"],"gpt_icon":0},{"id":"2529689806","title":"Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2529689806","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529689806?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:30","pubTimestamp":1745238600,"startTime":"0","endTime":"0","summary":"– The First Pivotal Phase 3 Trial to Demonstrate Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care Keytruda plus Chemotherapy in 1L mTNBC –。– Trodelvy Plus Keytruda Shows an Early Trend in Improvement for Overall Survival Versus Standard of Care in Patients with Previously Untreated PD-L1+  mTNBC –。\"These findings are the first to show the transformative potential of an antibody-drug conjugate combined with an immuno-oncology agent in early treatment lines of metastatic breast cancer,\" said Dietmar Berger, MD, PhD, Chief Medical Officer, Gilead Sciences. \"For patients with this difficult to treat type of breast cancer, these results potentially offer a new pathway that may redefine their treatment options.\". The significant and meaningful improvement in PFS demonstrated in ASCENT-04 further reinforces the potential of Trodelvy plus Keytruda as a much-needed new treatment option for patients with previously untreated inoperable  PD-L1+ loca","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/trodelvy-plus-keytruda-demonstrates-statistically-123000256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B1BXHZ80.USD","LU2106854487.HKD","BK4578","HR","SG9999002224.SGD","LU1035773651.USD","LU1066051225.USD","LU1069347547.HKD","SG9999001176.USD","LU0265550359.USD","PFS","PD","IE00BBT3K403.USD","IE00BKVL7J92.USD","LU0965509283.SGD","IE00BJT1NW94.SGD","SAR","ADC","LU0203347892.USD","SG9999002232.USD","LU1093756325.SGD","BK4007","LU2023250843.SGD","LU2112291526.USD","LU0234572021.USD","MCBS","CINV","MRK","LU1585245621.USD","SG9999014542.SGD","LU0965508806.USD","IE00BSNM7G36.USD","LU0861579265.USD","OS","LU0106261372.USD","LU0208291251.USD","LU1162221912.USD","LU2361045086.USD","LU0985320562.USD","IE000M9KFDE8.USD","LU2087621335.USD","BK4203","IE00BZ1G4Q59.USD","ORR","LU0203345920.USD","LU0109394709.USD","BK4585","LU1023059063.AUD","GILD","LU0234570918.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OS\",params:#limit:5,,,undefined,":[{"date":"2025-05-08","symbol":"OS","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":-0.06,"defaultRemindTime":1746734400000,"name":null,"time":"Post Market","dateTimestamp":1746676800000,"actualEps":null},{"market":"US","date":"2025-02-11","symbol":"OS","fiscalQuarterEnding":"2024/12","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1739250000000,"reportTimeType":"post","actualEps":0.07},{"market":"US","date":"2024-11-07","symbol":"OS","fiscalQuarterEnding":"2024/09","expectedEps":0,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-1.06},{"market":"US","date":"2024-09-03","symbol":"OS","fiscalQuarterEnding":"2024/06","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1725336000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.5556,"hold":0.1111,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5556,"analysts":18,"updateTime":1742529600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OS","date":"2025-04-28","current":-17.333565,"percent":0.89011,"low":-1655.61542,"twenty":-1414.621664,"median":-27.407231,"eighty":-18.799104,"high":-14.493656,"avg":-429.05566,"sd":616.357181,"marketCap":3747533991},"quantilePoints":[{"date":"2024-08-02","current":-402.058638,"twenty":-402.058638,"median":-402.058638,"eighty":-402.058638,"marketCap":4348264172},{"date":"2024-08-09","current":-394.529993,"twenty":-398.004752,"median":-394.602383,"eighty":-391.489578,"marketCap":4266841869},{"date":"2024-08-16","current":-420.156344,"twenty":-402.058638,"median":-395.977809,"eighty":-394.529993,"marketCap":4543990864},{"date":"2024-08-23","current":-418.563746,"twenty":-420.156344,"median":-400.248867,"eighty":-394.674774,"marketCap":4526766915},{"date":"2024-08-30","current":-439.701867,"twenty":-427.829772,"median":-415.668113,"eighty":-395.977809,"marketCap":4755375690},{"date":"2024-09-06","current":-1412.285699,"twenty":-434.093948,"median":-420.156344,"eighty":-395.977809,"marketCap":4652069092},{"date":"2024-09-13","current":-1421.532228,"twenty":-630.517125,"median":-426.381956,"eighty":-397.599363,"marketCap":4682527160},{"date":"2024-09-20","current":-1491.611188,"twenty":-1406.835113,"median":-428.55368,"eighty":-398.352228,"marketCap":4913367253},{"date":"2024-09-27","current":-1641.015636,"twenty":-1479.542034,"median":-435.672004,"eighty":-401.33473,"marketCap":5405505506},{"date":"2024-10-04","current":-1582.129844,"twenty":-1582.616503,"median":-445.348351,"eighty":-408.313205,"marketCap":5211535706},{"date":"2024-10-11","current":-1384.546111,"twenty":-1557.991535,"median":-1361.673117,"eighty":-414.50986,"marketCap":4560694889},{"date":"2024-10-18","current":-1422.505547,"twenty":-1506.405635,"median":-1387.466067,"eighty":-417.984619,"marketCap":4685733272},{"date":"2024-10-25","current":-1513.510863,"twenty":-1501.052381,"median":-1410.582391,"eighty":-419.837824,"marketCap":4985504782},{"date":"2024-10-31","current":-1488.204572,"twenty":-1545.825049,"median":-1419.58559,"eighty":-422.588676,"marketCap":4902145859},{"date":"2024-11-08","current":-29.444986,"twenty":-1544.267739,"median":-1421.532228,"eighty":-422.588676,"marketCap":5359016876},{"date":"2024-11-15","current":-29.547337,"twenty":-1525.190689,"median":-1414.232336,"eighty":-406.749563,"marketCap":5377644907},{"date":"2024-11-22","current":-27.361909,"twenty":-1504.167001,"median":-1405.472467,"eighty":-395.977809,"marketCap":4979894851},{"date":"2024-11-29","current":-26.339693,"twenty":-1496.769778,"median":-1384.546111,"eighty":-392.705744,"marketCap":4793850470},{"date":"2024-12-06","current":-28.33551,"twenty":-1493.655158,"median":-903.058146,"eighty":-29.829328,"marketCap":5157091209},{"date":"2024-12-13","current":-28.454992,"twenty":-1490.248542,"median":-439.701867,"eighty":-28.749622,"marketCap":5178836972},{"date":"2024-12-20","current":-27.223413,"twenty":-1484.895288,"median":-431.521704,"eighty":-28.258307,"marketCap":4954688343},{"date":"2024-12-27","current":-27.048786,"twenty":-1479.834029,"median":-428.191726,"eighty":-28.004145,"marketCap":4922906075},{"date":"2025-01-03","current":-25.973452,"twenty":-1479.444702,"median":-426.381956,"eighty":-27.732022,"marketCap":4727194212},{"date":"2025-01-10","current":-24.227183,"twenty":-1479.444702,"median":-422.183287,"eighty":-27.252823,"marketCap":4409371530},{"date":"2025-01-17","current":-26.460569,"twenty":-1468.54353,"median":-415.668113,"eighty":-26.869269,"marketCap":4815850013},{"date":"2025-01-24","current":-27.894348,"twenty":-1465.818237,"median":-402.058638,"eighty":-26.861301,"marketCap":5076799163},{"date":"2025-01-31","current":-27.407231,"twenty":-1462.314289,"median":-396.991281,"eighty":-26.925021,"marketCap":4988143362},{"date":"2025-02-07","current":-27.09474,"twenty":-1459.102337,"median":-394.674774,"eighty":-26.925021,"marketCap":4931269830},{"date":"2025-02-14","current":-19.646244,"twenty":-1457.642359,"median":-390.041762,"eighty":-26.782239,"marketCap":4247537655},{"date":"2025-02-21","current":-19.437413,"twenty":-1455.695721,"median":-30.305187,"eighty":-26.72172,"marketCap":4202388031},{"date":"2025-02-28","current":-18.385222,"twenty":-1452.094441,"median":-29.520901,"eighty":-26.562732,"marketCap":3974903390},{"date":"2025-03-07","current":-18.486889,"twenty":-1446.059864,"median":-28.777108,"eighty":-26.339693,"marketCap":3996883783},{"date":"2025-03-14","current":-16.449855,"twenty":-1440.122619,"median":-28.454992,"eighty":-26.179328,"marketCap":3556475076},{"date":"2025-03-21","current":-17.921046,"twenty":-1437.981318,"median":-28.198548,"eighty":-25.317223,"marketCap":3874548031},{"date":"2025-03-28","current":-18.76981,"twenty":-1430.38943,"median":-27.986257,"eighty":-24.094834,"marketCap":4058051659},{"date":"2025-04-04","current":-16.296269,"twenty":-1422.116219,"median":-27.889753,"eighty":-20.198845,"marketCap":3523269657},{"date":"2025-04-11","current":-15.87621,"twenty":-1419.974918,"median":-27.820821,"eighty":-19.520945,"marketCap":3432452458},{"date":"2025-04-17","current":-15.802935,"twenty":-1417.346957,"median":-27.682957,"eighty":-19.180725,"marketCap":3416610370},{"date":"2025-04-25","current":-17.317281,"twenty":-1415.400319,"median":-27.425612,"eighty":-18.846182,"marketCap":3744013527},{"date":"2025-04-28","current":-17.333565,"twenty":-1414.621664,"median":-27.407231,"eighty":-18.799104,"marketCap":3747533991}],"updateTime":1745925590335}}}